ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 44 of 50
JMBS 2018, 3(7): 260–266
Physical training and Sport. Medical and biological aspects of training athletes

Nonsteroid Anti-Inflammatory Drugs in Sports Medicine: Effectiveness and Risks

Gunina L. M. 1, Dmitriev A. V. 2

At present, in connection with the frequent intensification of the training process, the increase in the volume, intensity and duration of the loads, sportsmen, especially representatives of power and game sports, have got more frequent cases of the pathology of the ligaments and joints. This leads to the removal of the athlete from the training process. Moreover, it is often the reason for the further disability of qualified athletes. This situation requires a sports doctor, pharmacologist, nutritional specialist to use the most modern means of complex treatment and prevention of joint pathology, taking into account the absence of WADA in the forbidden list and features of the sport. Among the three most known and widely used medicines in sports medicine, nonsteroidal anti-inflammatory drugs occupy a special place not only because of the highest frequency of their use. This group of drugs is characterized primarily by a wide range of therapeutic activity. Its range covers all the main manifestations of articular pathology, such as: inflammation, pain, edema, mobility restriction, and a high speed of arresting lesions of the ligament-articular apparatus. However, non-steroidal anti-inflammatory drugs are also characterized by a wide range of side effects from the gastrointestinal tract, cardiovascular system, liver and kidneys, hematopoiesis system. Especially dangerous are these phenomena with the long-term use of non-steroidal anti-inflammatory drugs. That is why, they are recommended for oral administration in short courses and only during an exacerbation to eliminate pain. Today, celecoxib is one of the selective inhibitors of COX-2 widely used in domestic clinics. It is as effective as sodium diclofenac, ibuprofen and naproxen. Factors that predetermined the decision on the feasibility of using celecoxib drugs for the treatment of lesions of the ligaments and joints in athletes may be its quality, effectiveness, as well as a wide range of indications for use, in particular, the relief of pain of various geneses, as shown in numerous clinical studies with evidence level "A". Thus, the judgment on the criteria for choosing non-steroidal anti-inflammatory drugs should be based, firstly, on the tasks facing the sports doctor (short-term pain relief or long-term treatment). Secondly, we should take into account the characteristics of the sport and the specific loads. Thirdly, the doctor should pay attention to the characteristics of the organism of an athlete (initially present problems in the cardiovascular system, hematopoiesis, digestive tract, etc.).

Keywords: sports, injuries, articular apparatus diseases, nonsteroidal anti-inflammatory drugs, side effects

Full text: PDF (Rus) 222K

  1. Dmitriev AV, Gunina LM. Osnovy sportivnoy nutritsiologii. SPb: Izd-vo OOO RA «Russkiy Yuvelir»; 2018. S. 457-58. [Russian]
  2. Kalmin Oleg, Bochkareva Irina, Galkina Tatyana. Artrologiya; Uchebnoe posobie. Penza: PGMU; 2016. 64 s. [Russian]
  3. Nasonova VA. Rol tsiklooksigenazy-2 (COG-2) v etiologii boli. Terapevticheskiy arkhiv. 2001; 73(5): 56-7. [Russian]
  4. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015; 162(1): 46-54.
  5. Bannuru RR, Vaysbrot EE2, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 43(5): 593-9.
  6. Bruynzeel AM, Abou El Hassan MA, Schalkwijk C, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer. 2007; 96(6): 937‒43.
  7. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008; 12(11): 1-278, iii.
  8. Coaccioli S. Ketoprofen 2.5% gel: a clinical overview. Eur Rev Med Pharmacol Sci. 2011; 15(8): 943-9.
  9. Conaghan PG, Dickson J, Bolten W, Cevc G, Rother M. A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford). 2013; 52(7): 1303-12.
  10. Drawer S, Fuller CW. Propensity for osteoarthritis and lower limb joint pain in retired professional soccer players. Br J Sports Med. 2001; 35(6): 402-8.
  11. Driban JB, Hootman JM, Sitler MR, Harris KP, Cattano NM. Is Participation in Certain Sports Associated With Knee Osteoarthritis? A Systematic Review. J Athl Train. 2017; 52(6): 497-506.
  12. Fries JF, Williams CA, Bloch D. The relative toxicity of non-steroidal anti-inflammatory drugs. Arthritis and Rheumatism. 2001: 44(11): 1353-60.
  13. Garg Y, Singh J, Sohal HS, Gore R, Kumar A. Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study. Indian J. Pharmacol. 2017; 49(5): 383-9.
  14. Horváth VJ, Tabák GÁ, Szabó G, Putz Z, Koós CG, Lakatos P. [Cardiovascular side effects of non-steroidal anti-inflammatory drugs in the light of recent recommendations. Diclofenac is not more dangerous]. Orv Hetil. 2015; 156(13): 516-20.
  15. Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008; 16(2): 53-75.
  16. Kujala UM, Kaprio J, Sarna S. Osteoarthritis of weight bearing joints of lower limbs in former elite male athletes. Br Med J. 1994; 308(6923): 231-34.
  17. Lahoti A, Kalra BS, Tekur U. Evaluation of the analgesic and anti-inflammatory activity of fixed dose combination: non-steroidal anti-inflammatory drugs in experimental animals. Indian J Dent Res. 2014; 25(5): 551-4.
  18. Lefèvre-Colau MM, Nguyen C, Haddad R, Delamarche P, Paris G, Palazzo C, et al. Is physical activity, practiced as recommended for health benefit, a risk factor for osteoarthritis? Ann Phys Rehabil Med. 2016; 59(3): 196-206.
  19. Mateos JL. Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review. Drugs Today (Barc). 2010; 46(Suppl A): 1-25.
  20. Mazzuca SA, Brandt K, Anderson SL , Musick BS , Katz BP . The therapeutic approaches of community based primary care practitioners to osteoarthritis of the hip in an elderly patient. J Rheumatology. 1991; 18(10): 1593-600.
  21. Muraki S, Tanaka S, Yoshimura N. Epidemiology of knee osteoarthritis. OA Sports Medicine. 2013; 1(3): 21.
  22. Narsinghani T, Sharma R. Lead optimization on conventional non-steroidal anti-inflammatory drugs: an approach to reduce gastrointestinal toxicity. Lead optimization on conventional non-steroidal anti-inflammatory drugs: an approach to reduce gastrointestinal toxicity. Chem Biol Drug Des. 2014; 84(1): 1-23.
  23. Raynor MB, Kuhn JE. Utility of features of the patient's history in the diagnosis of atraumatic shoulder pain: a systematic review. J Shoulder Elbow Surg. 2016; 25(4): 688-94.
  24. Rogoveanu OC, Streba CT, Vere CC, Petrescu L, Trăistaru R. Superior digestive tract side effects after prolonged treatment with NSAIDs in patients with osteoarthritis. J Med Life. 2015; 8(4): 458-61.
  25. Saxon L, Finch C, Bass S. Sports participation, sports injuries and osteoarthritis: implications for prevention. Sports Med. 1999; 28(2): 123-35.
  26. Simoneti LF, Weckwerth GM, Dionísio TJ, Torres EA, Zupelari-Gonçalves P, Calvo AM, et al. Efficacy of Ketoprofen With or Without Omeprazole for Pain And Inflammation Control After Third Molar Removal. Braz Den J. 2018; 29(2): 140-9. 29898059.
  27. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther. 1994; 62(1-2): 175-91.
  28. Vannini F, Spalding T, Andriolo L, Berruto M, Denti M, Espregueira-Mendes J, et al. Sport and early osteoarthritis: the role of sport in aetiology, progression and treatment of knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2016; 24(6): 1786-96.–016–4090–5
  29. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013; 22(6): 559-70.
  30. Varrassi G, Hanna M, Macheras G, Montero A, Montes Perez A, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017; 33(6): 1165-73.
  31. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994; 107(1): 173-9.
  32. Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine (Baltimore). 2018; 97(31): e11649.